Report LibraryAll Reports
Datamonitor Healthcare Crohn's Disease KOL Interviews
Retail Price: $599.00*Included free with BioMedTracker Subscription - click here to log in
April 05, 2017Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD. The drugs discussed are listed below. The two interviews were combined into a single report.
Azasan (VRX), Cimzia, Cx601 (TIG), Entocort EC (PRGO), Entyvio (TKPYY), etrolizumab (RHHBF), filgotinib (GILD), GED 0301 (CELG), Humira (ABBV), Remicade (JNJ), Stelara (JNJ), Tysabri (BIIB), Xeljanz/Xeljanz XR (PFE).
As a special offer, we are pleased to make these two KOL interviews available free of charge to Biomedtracker clients.
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
|Indications Covered:||Crohn's Disease|